Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Phase 1 Dose-Escalation Study of Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00257881

Enrollment

Registered

2005-11-23

Start date

2005-11-30

Completion date

2006-12-31

Last updated

2007-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

Tumor

Brief summary

The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.

Interventions

DRUGCMD-193

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Malignant solid tumor progressed, or no standard treatment available * Tumor expression of Lewis Y antigen

Exclusion criteria

* Cancer therapy within 28 days before enrollment * Pregnant or breastfeeding women * Unstable or serious concurrent medical conditions

Design outcomes

Primary

Measure	Time frame
Dose Limiting Toxicity, Adverse Event	—

Secondary

Measure	Time frame
Pharmacokinetics parameters, Tumor assessment	—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026